Plus Therapeutics Inc (PSTV)Healthcare | Biotechnology | Houston, United States |
USD
|
Hot Take ↕ | Oct. 10, 2026, 5:50 a.m. UTC
The immediate outlook is severely bearish due to a catastrophic collapse in business fundamentals. The company is reporting negative gross margins of -83%, indicating that the cost to produce its therapies far exceeds the revenue generated, while operating losses are widening significantly. This is compounded by a sharp 2.9% decline in total revenue year-over-year, signaling a shrinking top line rather than a growing one. Despite the presence of cash on the balance sheet, the burn rate is aggressive, with free cash flow draining at over $15 million annually against a tiny market cap of roughly $26 million. The recent announcement of a reverse stock split and a ticker rebrand to 'CNSY' suggests a desperate attempt to reset the stock's psychology and potentially meet listing requirements, which often precedes further volatility or delisting risks. With no analyst coverage, a lack of price history to establish a trend, and a business model currently destroying value per share, there is no rational basis for a near-term entry or a long-term hold. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 6.061 |
| Revenue per Share | 1.12 |
| Market Cap | 26,640,680 |
| Trailing P/E | 0.18 |
| Forward P/E | -1.62 |
| Beta | 1.42 |
| Profit Margins | -230.24% |
| Website | https://plustherapeutics.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.7806857 |
| Address1 | 6,420 LEVIT GREEN BOULEVARD |
| Address2 | SUITE 210 |
| All Time High | 25,709,694.0 |
| All Time Low | 2.9 |
| Ask | 4.71 |
| Ask Size | 200 |
| Average Daily Volume10 Day | 80,839 |
| Average Volume | 159,311 |
| Average Volume10Days | 80,839 |
| Beta | 1.419 |
| Bid | 2.83 |
| Bid Size | 200 |
| Book Value | 1.743 |
| City | Houston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Currency | USD |
| Current Price | 3.87 |
| Current Ratio | 2.266 |
| Date Short Interest | 1,784,073,600 |
| Day High | 3.94 |
| Day Low | 3.62 |
| Debt To Equity | 6.061 |
| Ebitda | -18,486,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.663 |
| Enterprise To Revenue | 2.364 |
| Enterprise Value | 12,248,620 |
| Exchange | NCM |
| Exchange Timezone Name | UTC |
| Fax | 210 974 6901 |
| Fifty Day Average | 4.29706 |
| Fifty Two Week High | 23.425 |
| Fifty Two Week Low | 2.9 |
| Financial Currency | USD |
| First Trade Date Epoch Utc | 1,784,295,000 |
| Float Shares | 6,456,422 |
| Forward Eps | -2.395 |
| Forward P E | -1.6158663 |
| Free Cashflow | -15,108,250 |
| Full Time Employees | 28 |
| Fullday Change | 3.87 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 3.87 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -0.83095 |
| Gross Profits | -4,306,000 |
| Held Percent Insiders | 0.01835 |
| Held Percent Institutions | 0.13866 |
| Implied Shares Outstanding | 6,883,897 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,775,088,000 |
| Last Split Factor | 1:25 |
| Long Business Summary | Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas. |
| Long Name | Plus Therapeutics Inc |
| Market Cap | 26,640,680 |
| Max Age | 86,400 |
| Message Board Id | finmb_264193 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -11,931,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 14,799,768 |
| Number Of Analyst Opinions | 4 |
| Open | 3.65 |
| Operating Cashflow | -20,841,000 |
| Operating Margins | -6.9251003 |
| Payout Ratio | 0.0 |
| Peg Ratio | 2.45 |
| Phone | 737 255 7194 |
| Previous Close | 0.0 |
| Price Hint | 4 |
| Price To Book | 2.2203097 |
| Price To Sales Trailing12 Months | 5.1410036 |
| Profit Margins | -2.30239 |
| Quick Ratio | 2.07 |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Regular Market Day High | 3.94 |
| Regular Market Day Low | 3.62 |
| Regular Market Open | 3.65 |
| Regular Market Previous Close | 0.0 |
| Regular Market Volume | 96,526 |
| Return On Assets | -0.73818 |
| Revenue Growth | -0.029 |
| Revenue Per Share | 1.12 |
| Sand P52 Week Change | 0.1415559 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 6,883,897 |
| Shares Percent Shares Out | 0.103 |
| Shares Short | 709,382 |
| Shares Short Previous Month Date | 1,781,481,600 |
| Shares Short Prior Month | 1,115,738 |
| Short Name | PLUS THERAPEUTICS, Inc. |
| Short Percent Of Float | 0.1035 |
| Short Ratio | 2.97 |
| State | TX |
| Symbol | PSTV |
| Target High Price | 57.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 36.0 |
| Target Median Price | 37.5 |
| Time Zone Full Name | America/New_York |
| Time Zone Short Name | EDT |
| Total Cash | 15,114,000 |
| Total Cash Per Share | 2.196 |
| Total Debt | 725,000 |
| Total Revenue | 5,182,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | NaN |
| Trailing Eps | 21.56 |
| Trailing P E | 0.17949907 |
| Trailing Peg Ratio | None |
| Two Hundred Day Average | 7.8370523 |
| Underlying Symbol | PSTV |
| Uuid | bd166395-f6c5-3795-b061-111c794ae585 |
| Volume | 96,526 |
| Website | https://plustherapeutics.com |
| Zip | 77,021 |